Valienamine is a key precursor in the synthesis of voglibose, an effective antidiabetic drug that competitively inhibits α-glucosidase to suppress postprandial hyperglycemia; it serves as the core structural scaffold for various α-glucosidase inhibitors, including acarbose and voglibose, due to its unsaturated C7N aminocyclitol structure resembling α-D-glucose.